文献速递腹部CT

散发性胰岛素瘤在容积灌注CT上的动态强化模式及最佳肿瘤-实质对比时机

Sporadic insulinomas on volume perfusion CT: dynamic enhancement patterns and timing of optimal tumour-parenchyma contrast.
PubMed 文献 · Eur Radiol · 2017-01-20

回顾性纳入经手术证实的散发性胰岛素瘤患者,采用容积灌注CT评估强化模式并确定最佳肿瘤-实质对比时机。63个肿瘤呈现持续强化、短暂强化和无强化三种模式,最佳对比时机为腹主动脉阈值200 HU后9秒,此时肿瘤-实质对比为77.6±57.2 HU。双相/三相扫描可将强化肿瘤检出率从单相77.8%提高至84.1%和87.3%。

要点

  • 胰岛素瘤在容积灌注CT上有持续强化、短暂强化和无强化三种模式。
  • 最佳肿瘤-实质对比时机为腹主动脉阈值200 HU后9秒。
  • 双相或三相扫描可提高短暂强化肿瘤的检出率。

核心结论

  • 胰岛素瘤强化模式多样,肿瘤-实质对比具有时间依赖性,最佳强化时机为腹主动脉阈值200 HU后9秒,容积灌注CT可检出短暂强化的肿瘤。

研究设计与样本

  • 回顾性研究,连续纳入临床怀疑胰岛素瘤并接受容积灌注CT的患者,最终纳入经手术证实的散发性胰岛素瘤63个,排除家族性综合征患者,由两名放射科医生共识评估图像。

关键影像表现/征象

  • 持续强化模式(强化时间窗≥10秒)见于39个肿瘤(61.9%)。
  • 短暂强化模式(强化时间窗<10秒)见于19个肿瘤(30.2%)。
  • 无强化模式见于5个肿瘤(7.9%)。
  • 短暂强化和持续强化模式的胰岛素瘤灌注参数显著增高。

诊断标准与关键数值

  • 肿瘤-实质对比定义为肿瘤与实质的CT值差值,强化定义为肿瘤-实质对比>20 HU。
  • 最佳对比时机为腹主动脉阈值200 HU后9秒,此时肿瘤-实质对比为77.6±57.2 HU。
  • 腹主动脉阈值200 HU后9秒时,14个肿瘤(22.2%)无强化,其中9个漏诊了短暂强化。
  • 单相扫描发现77.8%肿瘤强化,双相扫描强化肿瘤增至84.1%,三相扫描增至87.3%。

临床应用与阅片要点

  • 阅片时应注意胰岛素瘤强化模式多样,包括持续强化、短暂强化和无强化。
  • 建议在腹主动脉阈值200 HU后9秒行动脉期扫描以捕捉最佳肿瘤-实质对比。
  • 对于短暂强化肿瘤,单相扫描可能漏诊,双相或三相扫描可提高检出率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess enhancement patterns of sporadic insulinomas on volume perfusion CT (VPCT), and to identify timing of optimal tumour-parenchyma contrast.

METHODS: Consecutive patients who underwent VPCT for clinically suspected insulinomas were retrospectively identified. Patients with insulinomas confirmed by surgery were included, and patients with familial syndromes were excluded. Two radiologists evaluated VPCT images in consensus. Tumour-parenchyma contrast at each time point was measured, and timing of optimal contrast was determined. Time duration of hyperenhancement (tumour-parenchyma contrast >20 Hounsfield units, HU) was recorded. Perfusion parameters were evaluated.

RESULTS: Three dynamic enhancement patterns were observed in 63 tumours: persistent hyperenhancement (hyperenhancement time window ≥10 s) in 39 (61.9%), transient hyperenhancement (hyperenhancement <10 s) in 19 (30.2%) and non-hyperenhancement in 5 (7.9%). Timing of optimal contrast was 9 s after abdominal aorta threshold (AAT) of 200 HU, with tumour-parenchyma contrast of 77.6 ± 57.2 HU. At 9 s after AAT, 14 (22.2%) tumours were non-hyperenhancing, nine of which had missed transient hyperenhancement. Insulinomas with transient and persistent hyperenhancement patterns had significantly increased perfusion.

CONCLUSIONS: Insulinomas have variable enhancement patterns. Tumour-parenchyma contrast is time-dependent. Optimal timing of enhancement is 9 s after AAT. VPCT enables tumour detection even if the hyperenhancement is transient.

KEY POINTS: • Enhancement patterns of insulinomas are variable and tumour-parenchyma contrast is time-dependent. • An optimized single-phase scan found 77.8% tumours to be hyperenhancing. • Hyperenhancing tumours increase to 84.1% and 87.3% with biphasic/triphasic scan. • Volume perfusion CT enables detection of insulinomas with missed transient hyperenhancement.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhu L, Wu WM, Xue HD, et al. Sporadic insulinomas on volume perfusion CT: dynamic enhancement patterns and timing of optimal tumour-parenchyma contrast. Eur Radiol. 2017. PMID: 28108839. doi:10.1007/s00330-016-4709-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。